Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

Blood

Volumn 110, Issue 10, 2007, Pages 3557-3560

  Richardson, Paul G ^a   Sonneveld, Pieter ^b   Schuster, Michael ^c   Irwin, David ^d   Stadtmauer, Edward ^e   Facon, Thierry ^f   Harousseau, Jean Luc ^g   Ben Yehuda, Dina ^h   Lonial, Sagar ⁱ   Goldschmidt, Hartmut ^j   Reece, Donna ^k   San Miguel, Jesus ^l   Bladé, Joan ^m   Boccadoro, Mario ⁿ   Cavenagh, Jamie ^o   Alsina, Melissa ^p   Rajkumar, S Vincent ^q   Lacy, Martha ^q   Jakubowiak, Andrzej ^r   Dalton, William ^p   Boral, Anthony ^s   Esseltine, Dixie Lee ^s   Schenkein, David ^t   Anderson, Kenneth C ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Alta Bates Cancer Center   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

ⁱ EMORY UNIVERSITY   (United States)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l UNIVERSITY OF SALAMANCA   (Spain)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ UNIVERSITY OF TURIN   (Italy)

^o ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q MAYO CLINIC   (United States)

^r UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^s MILLENNIUM PHARMACEUTICALS INC   (United States)

^t GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL RATE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 35148825003     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-036947     Document Type: Article

References (24)

1. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
2. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
4. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
5. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777-3784.
6. Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005;104:2141-2148.
7. Sonneveld P, Richardson PG, Schuster MW, et al. Bortezomib at first relapse is superior to high-dose dexamethasone and more effective than when given later in relapsed multiple myeloma [abstract]. Haematologica. 2005;90:146-147. Abstract P140.721.
8. Vogl DT, Stadtmauer EA, Richardson PG, et al. Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial [abstract]. J Clin Oncol. 2006;23:433s. Abstract 7546.
9. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91:929-934.
10. Kropff MH, Bisping G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29:587-590.
11. Kropff M, Bisping G, Liebisch P, et al. Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma [abstract]. Blood. 2005;106:716a. Abstract 2549.
12. Reece DE, Piza GR, Trudel S, et al. A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma [abstract]. Blood. 2006;108:1009a. Abstract 3536.
13. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T [abstract]. Blood. 2005;106:717a. Abstract 2552.
14. Teoh G, Tan D, Hwang W, et al. Addition of bortezomib to thalidomide, dexamethasone and zoledronic acid (VTD-Z regimen) significantly improves complete remission rates in patients with relapsed/refractory multiple myeloma [abstract]. J Clin Oncol. 2006;24:683s. Abstract 17537.
15. Richardson PG, Jagannath S, Avigan DE, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]. Blood. 2006;108:124a. Abstract 405.
16. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058-3065.
17. Hollmig K, Stover J, Talamo G, et al. Bortezomib (Velcade™) + adriamycin™ + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM) [abstract]. Blood. 2004;104:659a. Abstract 2399.
18. Chanan-Khan AA, Padmanabhan S, Miller KC, et al. Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma [abstract]. Blood. 2006;108:1010a. Abstract 3539.
19. Friedman J, Al-Zoubi A, Kaminski M, Kendall T, Jakubowiak A. A new model predicting at least a very good partial response in patients with multiple myeloma after 2 cycles of Velcade-based therapy [abstract]. Haematologica. 2006;91:273. Abstract P. 0741.
20. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24:937-944.
21. Popat R, Williams C, Cook M, et al. A phase I/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma [abstract]. Blood. 2006;108:1011a. Abstract 3542.
22. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007;109:2767-2772.
23. Terpos E, Anagnostopoulos A, Heath D, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective regimen for relapsed/refractory myeloma and reduces serum levels of Dickkopf-1, RANKL, MIP-1α and angiogenic cytokines [abstract]. Blood. 2006;108:1010a-1011a. Abstract 3541.
24. Richardson P, Chanan-Khan AA, Lonial S, et al. A multicenter phase 1 clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pretreated patients with relapsed refractory multiple myeloma (MM) [abstract]. Blood. 2006;108:124a-125a. Abstract 406.